Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Nasdaq

Check Out What Whales Are Doing With INTC

Someone with a lot of money to spend has taken a bearish stance on Intel (NASDAQ:INTC). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

Insurance Stocks Moving In Tuesday's Intraday Session

According to Benzinga Pro following are the gainers and losers in Insurance industry for today's Intraday session.

Benzinga

$1000 Invested In Intuitive Surgical 10 Years Ago Would Be Worth This Much

Intuitive Surgical (NASDAQ:ISRG) has outperformed the market over the past 10 years by 2.63% on an annualized basis producing an average annual return of 14.43%. Currently, Intuitive Surgical has a market capitalization of $85.51 billion.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Tesla Recalls And Replaces One Customer's Model X

While Tesla Inc (NASDAQ: TSLA) has had quite a

Benzinga

Several Young Athletes To Introduce NFTs On DraftKings Marketplace - Guess Who

DraftKings Inc (NASDAQ:DKNG) has partnered with memorabilia and NFT company Metabilia to supply NFT on DraftKings Marketplace. The collaboration has introduced Membership NFTs for fans to chronicle the careers of top young players. The NFTs will feature star major leaguers beginning with Vladimir Guerrero Jr, Ronald Acuña Jr, Shane Bieber, Wander Franco, Joe…

Benzinga

Pure Sunfarms And NOYA Bring Cookies Sun-Grown Cannabis Flower To Ontario

Pure Sunfarms Corp. a wholly-owned subsidiary of Village Farms International, Inc. (NASDAQ: VFF) and NOYA Cannabis Inc. announced that Cookies sun-grown flower will be available in Ontario this month.

Benzinga

HEXO Launches New At-the-Market Offering, Here Are The Details

HEXO Corp. (NASDAQ: HEXO) (TSX:HEXO) has established an at-the-market equity program that allows the company to issue and sell up to $40 million of common shares in company capital from the treasury to the public, from time to time, at the company’s discretion.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Henry Schein Q1 Earnings Beat Street View, Sticks To FY22 Guidance

Henry Schein Inc (NASDAQ:HSIC) posts Q1 FY22 sales of $3.32 billion, beating the consensus of $3.13 billion, up 8.7% Y/Y, including 7.7% internal growth in local currencies, 2.4% growth from acquisitions, and a 1.4% decline related to foreign currency exchange. Q4 internal sales growth in local currencies, excluding personal protective equipment and COVID-19…

Benzinga

Stocks That Hit 52-Week Lows On Tuesday

Tuesday's session saw 211 companies set new 52-week lows.

Benzinga

Mid-Day Market Update: Dow Jumps 100 Points; Spero Therapeutics Shares Plunge

U.S. stocks traded higher midway through trading, with the Dow Jones gaining over 100 points on Tuesday.

Benzinga

41 Stocks Moving In Tuesday's Mid-Day Session

Gainers SoundHound AI, Inc. (NASDAQ: SOUN) shares jumped 47.4% to $16.13. The company recently completed a SPAC merger deal last week and began trading on Thursday.

Benzinga

Where Expedia Group Stands With Analysts

Analysts have provided the following ratings for Expedia Group (NASDAQ:EXPE) within the last quarter:

Benzinga

Earnings Outlook For United Therapeutics

United Therapeutics (NASDAQ:UTHR) is set to give its latest quarterly earnings report on Wednesday, 2022-05-04. Here's what investors need to know before the announcement. Analysts estimate that United Therapeutics will report an earnings per share (EPS) of $3.34.

Benzinga

Where Axsome Therapeutics Stands With Analysts

Analysts have provided the following ratings for Axsome Therapeutics (NASDAQ:AXSM) within the last quarter:

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Earnings Preview: Conformis

Conformis (NASDAQ:CFMS) is set to give its latest quarterly earnings report on Wednesday, 2022-05-04. Here's what investors need to know before the announcement. Analysts estimate that Conformis will report an earnings per share (EPS) of $-0.07.

Benzinga

Analyst Ratings for Vertex Pharmaceuticals

Over the past 3 months, 4 analysts have published their opinion on Vertex Pharmaceuticals (NASDAQ:VRTX) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Benzinga

Earnings Preview For IDEXX Laboratories

IDEXX Laboratories (NASDAQ:IDXX) is set to give its latest quarterly earnings report on Wednesday, 2022-05-04. Here's what investors need to know before the announcement. Analysts estimate that IDEXX Laboratories will report an earnings per share (EPS) of $2.26.

Benzinga

$1000 Invested In Lam Research 20 Years Ago Would Be Worth This Much

Lam Research (NASDAQ:LRCX) has outperformed the market over the past 20 years by 9.01% on an annualized basis producing an average annual return of 16.12%. Currently, Lam Research has a market capitalization of $67.00 billion.

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Here's How Much $100 Invested In Marriott Intl 20 Years Ago Would Be Worth Today

Marriott Intl (NASDAQ:MAR) has outperformed the market over the past 20 years by 4.33% on an annualized basis producing an average annual return of 11.44%. Currently, Marriott Intl has a market capitalization of $56.53 billion.

Benzinga

What 6 Analyst Ratings Have To Say About EverQuote

EverQuote (NASDAQ:EVER) has observed the following analyst ratings within the last quarter:

Benzinga

Piper Sandler Maintains Overweight Rating for ZoomInfo Technologies: Here's What You Need To Know

Piper Sandler has decided to maintain its Overweight rating of ZoomInfo Technologies (NASDAQ:ZI) and lower its price target from $75.00 to $65.00. Shares of ZoomInfo Technologies are trading up 3.7% over the last 24 hours, at $51.02 per share.

Benzinga

Raymond James Maintains Outperform Rating for Galmed Pharmaceuticals: Here's What You Need To Know

Raymond James has decided to maintain its Outperform rating of Galmed Pharmaceuticals (NASDAQ:GLMD) and lower its price target from $14.00 to $5.00. Shares of Galmed Pharmaceuticals are trading down 22.69% over the last 24 hours, at $0.94 per share.

Benzinga

Analyst Ratings for Beyond Meat

Over the past 3 months, 9 analysts have published their opinion on Beyond Meat (NASDAQ:BYND) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Benzinga

Roe V. Wade News Spurs Google Search Spike For 'U-Haul': Here's What It Means

Following the news of Monday night’s leaked draft of a potential U.S. Supreme Court overturn of the 1973 Roe v.

Benzinga

What's Going On With Bitcoin- And Ethereum-Related Stock MicroStrategy?

MicroStrategy Incorporated (NASDAQ: MSTR) shares are trading lower by 2.00% at $358.60. Traders and investors are watching for the company’s first-quarter earnings report, which is confirmed for Tuesday’s after-hours session.

1 … 577 578 579 580

People

Vladimir Guerrero Jr.

32 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.